Biomarkers such as PD-L1 expression, high TMB, and increased tumor infiltration of CD8+ T cells all correlate with the therapeutic efficacy of PD-1 antibodies, but none of these are sufficient to precisely select patient populations. This evidence concerns the gene PDCD1 and neoplasm.